Natera Reports Third Quarter 2026 Financial Results
Natera Reports Third Quarter 2026 Financial Results AUSTIN, Texas, November 5, 2026 /BUSINESS WIRE/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30, 2026.
• Generated total revenues of $794.0 million in the third quarter of 2026, compared to $592.2 million in the third quarter of 2025, an increase of 34.1%.
• Generated a gross margin 1 of 64.7% in the third quarter of 2026, compared to a gross margin 1 of 64.9% in the third quarter of 2025. Excluding revenue true- ups, third quarter non-GAAP gross margin 2 increased by 137 basis points over the second quarter of 2026.
• Processed approximately 1,093,100 tests in the third quarter of 2026, compared to approximately 893,600 tests in the third quarter of 2025, an increase of 22.3%.
• Processed approximately 339,500 oncology tests in the third quarter of 2026, compared to approximately 211,000 in the third quarter of 2025, an increase of 60.9%. Clinical molecular residual disease (MRD) oncology units grew 32,700 units over the second quarter of 2026.
• Increased cash by approximately $5.7 million 3 as of September 30, 2026 compared to June 30, 2026.
• Raised 2026 annual revenue guidance by $140 million at the midpoint, from $2.850 billion - $2.910 billion to $3.005 billion - $3.035 billion.
Total revenues were $794.0 million in the third quarter of 2026 compared to $592.2 million in the third quarter of 2025, an increase of 34.1%. The increase in revenues was driven by an increase in volume and average selling price improvements.
Natera processed approximately 1,093,100 tests in the third quarter of 2026, including approximately 1,080,300 tests accessioned in its laboratory, compared to approximately 893,600 tests processed, including approximately 879,700 tests accessioned in its laboratory, in the third quarter of 2025.
In the third quarter of 2026, Natera recognized revenue on approximately 1,024,800 tests for which results were reported to customers in the period (tests reported), including approximately 1,012,100 tests reported from its laboratory, compared to approximately 832,900 tests reported, including approximately 819,900 tests reported from its laboratory, in the third quarter of 2025, an increase of 23.0% from the prior period.
Gross profit 1 for the three months ended September 30, 2026 and 2025 was $513.5 million and $384.4 million, respectively, representing a gross margin 1 of 64.7% and 64.9%, respectively. This was primarily as a result of higher revenues and continued progress in reducing cost of revenues, offset by a smaller benefit from changes in estimates. Changes in estimates for the three months ended September 30, 2026 and 2025 increased revenue and, as a result, increased gross margin 1 by 1.5% and 3.6%, respectively, and increased gross profit 1 by $32.3 million and $55.1 million, respectively. The decrease in the change in estimate reflects the continued accumulation of historical collection experience, which has resulted in our estimates of variable consideration at the time of revenue recognition more closely approximating subsequent cash collections.
Gross margin 1 for the three months ended June 30, 2026 was 64.5%. Excluding the change in estimates in revenue accruals of approximately $32.3 million and $52.3 million during the three months ended September 30, 2026 and June 30, 2026, respectively, Natera's non-GAAP gross margin 2 increased by approximately 1.4% sequentially.
Total operating expenses, representing research and development expenses and selling, general and administrative expenses, for the third quarter of 2026 was $576.1 million, compared to $482.0 million in the same period of the prior year, an increase of 19.5%. The increase was primarily driven by headcount growth to support new product offerings as well as increases in clinical trial expenses. Amortization of acquired intangible assets for the third quarter of 2026 was $5.7 million. No such amortization occurred in the third quarter of 2025.
Loss from operations for the third quarter of 2026 was $68.3 million compared to $97.6 million for the same period of the prior year.
Natera’s net loss for the third quarter of 2026 was $59.9 million, or ($0.42) per diluted share, compared to a net loss of $87.5 million, or ($0.64) per diluted share, in the third quarter of 2025. Weighted average shares outstanding were 144.1 million in the third quarter of 2026 compared to 137.2 million for the same period in the prior year.
At September 30, 2026, Natera held approximately $1,097.2 million in cash, cash equivalents, and restricted cash, compared to $1,076.1 million as of December 31, 2025. As of September 30, 2026, Natera had a total outstanding debt balance of $80.3 million, including accrued interest under its line of credit with UBS at a variable interest rate of 30-day SOFR plus 50 bps.
Natera anticipates 2026 total revenue of $3.005 billion to $3.035 billion; gross margin 1 to be approximately 64% to 66%; selling, general and administrative costs to be approximately $1.225 billion to $1.300 billion; research and development costs to be $825 million to $925 million; and cash flow to be positive.
Unit QTD 2026 QTD 2025 Definition Tests accessioned in our Tests processed 1,093,100 893,600 laboratory plus units processed outside of our laboratory Tests accessioned 1,080,300 879,700 Tests accessioned in our laboratory Tests reported 1,024,800 832,900 Total tests reported Total tests reported in Tests reported in our 1,012,100 819,900 our laboratory less laboratory units reported outside of our laboratory
Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, San Carlos, California, and Boulder, Colorado. For more information, visit www.natera.com.
This press release contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts, including statements regarding our market opportunity, anticipated products and launch schedules, reimbursement coverage, product costs, and gross margins, commercial and strategic partnerships and acquisitions, user experience, clinical trials and studies, and our strategies, goals and general business and market conditions, are forward-looking statements. Any forward-looking statements contained in this press release are based upon Natera’s current plans, estimates, and expectations, as of the date of this release, and are not a representation that such plans, estimates, or expectations will be achieved.
These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including: we face numerous uncertainties and challenges in achieving our financial projections and goals; we may be unable to further increase the use and adoption of our products through our direct sales efforts or through
our laboratory partners; we have incurred net losses since our inception and we anticipate that we will continue to incur net losses for the foreseeable future; our quarterly results may fluctuate from period to period; unless otherwise indicated, all financial data for the current and prior quarters are unaudited and subject to adjustment in connection with the completion of our quarterly and annual financial reporting processes; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we may be unable to compete successfully with existing or future products or services offered by our competitors; we may engage in acquisitions, dispositions or other strategic transactions that may not achieve our anticipated benefits and could otherwise disrupt our business, cause dilution to our stockholders or reduce our financial resources; our products may not perform as expected; the results of our clinical studies may not support the use and reimbursement of our tests, particularly for microdeletions screening, and may not be able to be replicated in later studies required for regulatory approvals or clearances; if either of our primary CLIA- certified laboratories becomes inoperable, we will be unable to perform our tests and our business may be harmed; we rely on a limited number of suppliers or, in some cases, single suppliers, for some of our laboratory instruments and materials and may not be able to find replacements or immediately transition to alternative suppliers; if we are unable to successfully scale our operations, our business could suffer; the marketing, sale, and use of Panorama and our other products could result in substantial damages arising from product liability or professional liability claims that exceed our resources; we may be unable to expand, obtain or maintain third-party payer coverage and reimbursement for our tests, and we may be required to refund reimbursements already received; third-party payers may withdraw coverage or provide lower levels of reimbursement due to changing policies, billing complexities or other factors; we could incur substantial costs and delays complying with governmental regulations; litigation and other regulatory or governmental proceedings related to our intellectual property or the commercialization of our tests, are costly, time-consuming, could result in our obligation to pay material judgments or incur material settlement costs, and could limit our ability to commercialize our tests; and any inability to effectively protect our proprietary technology could harm our competitive position or our brand.
We discuss these and other risks and uncertainties in greater detail in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our periodic reports on Forms 10-K and 10-Q and in other filings that we make with the SEC from time to time. These documents are available on our website at www.natera.com under the Investor Relations section and on the SEC’s website at www.sec.gov.
We operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. In light of these risks, uncertainties and assumptions, you should not place undue reliance on our forward-looking statements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations. References: 1. Gross profit is calculated as GAAP total revenues less GAAP cost of revenues. Gross margin is calculated as gross profit divided by GAAP total revenues.
2. Excluding the change in estimates in revenue accruals of approximately $32.3 million and $52.3 million during the three months ended September 30, 2026 and June 30, 2026, respectively, Natera’s non-GAAP gross margin increased by approximately 1.4% sequentially.
September 30, December 31, 2026 2025 ────────────────────────────────────────────────────────────────────────────── -1 Assets Current assets: Cash, cash equivalents and $ 1,097,195 $ 1,076,140 restricted cash Accounts receivable, net of allowance of 471,354 296,528 $6,231 in 2026 and $8,018 in 2025 Inventory 91,704 68,443 Prepaid expenses and other current 62,359 55,828 assets Total current 1,722,612 1,496,939 assets Property and 353,954 241,184 equipment, net Operating lease 129,445 108,541 right-of-use assets Goodwill 141,100 141,070 Intangible assets 353,044 373,713 Other assets 48,260 36,897 Total assets $ 2,748,415 $ 2,398,344 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 120,176 $ 33,156 Accrued 112,541 92,603 compensation Contingent consideration 45,873 21,580 payable, current portion Deferred revenue, 36,596 24,907 current portion Short-term debt 80,295 80,323 financing Other accrued 217,416 188,659 liabilities Total current 612,897 441,228 liabilities Contingent consideration 83,187 96,780 payable, long-term portion Deferred tax liability, 701 701 long-term portion Operating lease liabilities, 142,617 118,473 long-term portion Deferred revenue, 15,781 17,062 long-term portion Other liabilities 23,674 11,687 Total liabilities 878,857 685,931 Commitments and contingencies Stockholders’ equity: Common stock(2) 14 14 Additional paid in 4,857,666 4,488,679 capital Accumulated deficit -2,987,994 -2,776,022 Accumulated other -128 -258 comprehensive loss Total stockholders’ 1,869,558 1,712,413 equity Total liabilities and stockholders’ $ 2,748,415 $ 2,398,344 equity
(1) The consolidated balance sheet at December 31, 2025 has been derived from the audited consolidated financial statements at that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.
(2) As of September 30, 2026 and December 31, 2025, there were approximately 144,345,000 and 139,693,000 shares of common stock, respectively, issued and outstanding.
Full text with the tables
Exhibit 99.1
Natera Reports Third Quarter 2026 Financial Results
AUSTIN, Texas, November 5, 2026 /BUSINESS WIRE/ — Natera, Inc. (NASDAQ: NTRA), a
global leader in cell-free DNA and precision medicine, today reported its
financial results for the third quarter ended September 30, 2026.
Recent Financial Highlights
• Generated total revenues of $794.0 million in the third quarter of 2026,
compared to $592.2 million in the third quarter of 2025, an increase of 34.1%.
• Generated a gross margin 1 of 64.7% in the third quarter of 2026, compared to
a gross margin 1 of 64.9% in the third quarter of 2025. Excluding revenue true-
ups, third quarter non-GAAP gross margin 2 increased by 137 basis points over
the second quarter of 2026.
• Processed approximately 1,093,100 tests in the third quarter of 2026, compared
to approximately 893,600 tests in the third quarter of 2025, an increase of
22.3%.
• Processed approximately 339,500 oncology tests in the third quarter of 2026,
compared to approximately 211,000 in the third quarter of 2025, an increase of
60.9%. Clinical molecular residual disease (MRD) oncology units grew 32,700
units over the second quarter of 2026.
• Increased cash by approximately $5.7 million 3 as of September 30, 2026
compared to June 30, 2026.
• Raised 2026 annual revenue guidance by $140 million at the midpoint, from
$2.850 billion - $2.910 billion to $3.005 billion - $3.035 billion.
Third Quarter Ended September 30, 2026 Financial Results
Total revenues were $794.0 million in the third quarter of 2026 compared to
$592.2 million in the third quarter of 2025, an increase of 34.1%. The increase
in revenues was driven by an increase in volume and average selling price
improvements.
Natera processed approximately 1,093,100 tests in the third quarter of 2026,
including approximately 1,080,300 tests accessioned in its laboratory, compared
to approximately 893,600 tests processed, including approximately 879,700 tests
accessioned in its laboratory, in the third quarter of 2025.
In the third quarter of 2026, Natera recognized revenue on approximately
1,024,800 tests for which results were reported to customers in the period
(tests reported), including approximately 1,012,100 tests reported from its
laboratory, compared to approximately 832,900 tests reported, including
approximately 819,900 tests reported from its laboratory, in the third quarter
of 2025, an increase of 23.0% from the prior period.
Gross profit 1 for the three months ended September 30, 2026 and 2025 was $513.5
million and $384.4 million, respectively, representing a gross margin 1 of 64.7%
and 64.9%, respectively. This was primarily as a result of higher revenues and
continued progress in reducing cost of revenues, offset by a smaller benefit
from changes in estimates. Changes in estimates for the three months ended
September 30, 2026 and 2025 increased revenue and, as a result, increased gross
margin 1 by 1.5% and 3.6%, respectively, and increased gross profit 1 by $32.3
million and $55.1 million, respectively. The decrease in the change in estimate
reflects the continued accumulation of historical collection experience, which
has resulted in our estimates of variable consideration at the time of revenue
recognition more closely approximating subsequent cash collections.
Gross margin 1 for the three months ended June 30, 2026 was 64.5%. Excluding the
change in estimates in revenue accruals of approximately $32.3 million and $52.3
million during the three months ended September 30, 2026 and June 30, 2026,
respectively, Natera's non-GAAP gross margin 2 increased by approximately 1.4%
sequentially.
Total operating expenses, representing research and development expenses and
selling, general and administrative expenses, for the third quarter of 2026 was
$576.1 million, compared to $482.0 million in the same period of the prior year,
an increase of 19.5%. The increase was primarily driven by headcount growth to
support new product offerings as well as increases in clinical trial expenses.
Amortization of acquired intangible assets for the third quarter of 2026 was
$5.7 million. No such amortization occurred in the third quarter of 2025.
Loss from operations for the third quarter of 2026 was $68.3 million compared to
$97.6 million for the same period of the prior year.
Natera’s net loss for the third quarter of 2026 was $59.9 million, or ($0.42)
per diluted share, compared to a net loss of $87.5 million, or ($0.64) per
diluted share, in the third quarter of 2025. Weighted average shares outstanding
were 144.1 million in the third quarter of 2026 compared to 137.2 million for
the same period in the prior year.
At September 30, 2026, Natera held approximately $1,097.2 million in cash, cash
equivalents, and restricted cash, compared to $1,076.1 million as of December
31, 2025. As of September 30, 2026, Natera had a total outstanding debt balance
of $80.3 million, including accrued interest under its line of credit with UBS
at a variable interest rate of 30-day SOFR plus 50 bps.
Financial Outlook
Natera anticipates 2026 total revenue of $3.005 billion to $3.035 billion; gross
margin 1 to be approximately 64% to 66%; selling, general and administrative
costs to be approximately $1.225 billion to $1.300 billion; research and
development costs to be $825 million to $925 million; and cash flow to be
positive.
Test Volume Summary
Unit QTD 2026 QTD 2025 Definition
Tests accessioned in our
Tests processed 1,093,100 893,600 laboratory plus units
processed outside of our
laboratory
Tests accessioned 1,080,300 879,700 Tests accessioned in our
laboratory
Tests reported 1,024,800 832,900 Total tests reported
Total tests reported in
Tests reported in our 1,012,100 819,900 our laboratory less
laboratory units reported outside
of our laboratory
About Natera
Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to
oncology, women’s health, and organ health. We aim to make personalized genetic
testing and diagnostics part of the standard-of-care to protect health and
inform earlier, more targeted interventions that help lead to longer, healthier
lives. Natera’s tests are supported by more than 400 peer-reviewed publications
that demonstrate excellent performance. Natera operates ISO 13485-certified and
CAP-accredited laboratories certified under the Clinical Laboratory Improvement
Amendments (CLIA) in Austin, Texas, San Carlos, California, and Boulder,
Colorado. For more information, visit www.natera.com.
Conference Call Information
Event: Natera’s Third Quarter Financial Results Conference Call
Date: Thursday, November 5, 2026
────────────────────────────────────────────────────────────────────────────
Time: 1:30 p.m. PT (4:30 p.m. ET)
Live Dial-In: 1-833-461-5787 (Domestic)
1-585-542-9983 (International)
Conference ID: 221 556 643
Webcast Link: https://events.q4inc.com/attendee/221556643
Forward-Looking Statements
This press release contains forward-looking statements under the meaning of the
Private Securities Litigation Reform Act of 1995. All statements other than
statements of historical facts, including statements regarding our market
opportunity, anticipated products and launch schedules, reimbursement coverage,
product costs, and gross margins, commercial and strategic partnerships and
acquisitions, user experience, clinical trials and studies, and our strategies,
goals and general business and market conditions, are forward-looking
statements. Any forward-looking statements contained in this press release are
based upon Natera’s current plans, estimates, and expectations, as of the date
of this release, and are not a representation that such plans, estimates, or
expectations will be achieved.
These forward-looking statements are subject to known and unknown risks and
uncertainties that may cause actual results to differ materially, including: we
face numerous uncertainties and challenges in achieving our financial
projections and goals; we may be unable to further increase the use and adoption
of our products through our direct sales efforts or through
our laboratory partners; we have incurred net losses since our inception and we
anticipate that we will continue to incur net losses for the foreseeable future;
our quarterly results may fluctuate from period to period; unless otherwise
indicated, all financial data for the current and prior quarters are unaudited
and subject to adjustment in connection with the completion of our quarterly and
annual financial reporting processes; our estimates of market opportunity and
forecasts of market growth may prove to be inaccurate; we may be unable to
compete successfully with existing or future products or services offered by our
competitors; we may engage in acquisitions, dispositions or other strategic
transactions that may not achieve our anticipated benefits and could otherwise
disrupt our business, cause dilution to our stockholders or reduce our financial
resources; our products may not perform as expected; the results of our clinical
studies may not support the use and reimbursement of our tests, particularly for
microdeletions screening, and may not be able to be replicated in later studies
required for regulatory approvals or clearances; if either of our primary CLIA-
certified laboratories becomes inoperable, we will be unable to perform our
tests and our business may be harmed; we rely on a limited number of suppliers
or, in some cases, single suppliers, for some of our laboratory instruments and
materials and may not be able to find replacements or immediately transition to
alternative suppliers; if we are unable to successfully scale our operations,
our business could suffer; the marketing, sale, and use of Panorama and our
other products could result in substantial damages arising from product
liability or professional liability claims that exceed our resources; we may be
unable to expand, obtain or maintain third-party payer coverage and
reimbursement for our tests, and we may be required to refund reimbursements
already received; third-party payers may withdraw coverage or provide lower
levels of reimbursement due to changing policies, billing complexities or other
factors; we could incur substantial costs and delays complying with governmental
regulations; litigation and other regulatory or governmental proceedings related
to our intellectual property or the commercialization of our tests, are costly,
time-consuming, could result in our obligation to pay material judgments or
incur material settlement costs, and could limit our ability to commercialize
our tests; and any inability to effectively protect our proprietary technology
could harm our competitive position or our brand.
We discuss these and other risks and uncertainties in greater detail in the
sections entitled “Risk Factors” and “Management’s Discussion and Analysis of
Financial Condition and Results of Operations” in our periodic reports on Forms
10-K and 10-Q and in other filings that we make with the SEC from time to time.
These documents are available on our website at www.natera.com under the
Investor Relations section and on the SEC’s website at www.sec.gov.
We operate in a very competitive and rapidly changing environment. New risks
emerge from time to time. It is not possible for our management to predict all
risks, nor can we assess the impact of all factors on our business or the extent
to which any factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking statement. In
light of these risks, uncertainties and assumptions, you should not place undue
reliance on our forward-looking statements. Except as required by law, we
undertake no obligation to update publicly any forward-looking statements for
any reason after the date of this presentation to conform these statements to
actual results or to changes in our expectations.
References:
1. Gross profit is calculated as GAAP total revenues less GAAP cost of revenues.
Gross margin is calculated as gross profit divided by GAAP total revenues.
2. Excluding the change in estimates in revenue accruals of approximately $32.3
million and $52.3 million during the three months ended September 30, 2026 and
June 30, 2026, respectively, Natera’s non-GAAP gross margin increased by
approximately 1.4% sequentially.
3. Includes GAAP cash, cash equivalents and restricted cash.
Contacts
Investor Relations
Mike Brophy, CFO, Natera, Inc., [email protected]
Media
Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., [email protected]
Natera, Inc.
Consolidated Balance Sheets
(Unaudited)
(in thousands, except shares)
September 30, December 31,
2026 2025
──────────────────────────────────────────────────────────────────────────────
-1
Assets
Current assets:
Cash, cash
equivalents and $ 1,097,195 $ 1,076,140
restricted
cash
Accounts
receivable, net of
allowance of 471,354 296,528
$6,231 in 2026 and
$8,018 in 2025
Inventory 91,704 68,443
Prepaid expenses
and other current 62,359 55,828
assets
Total current 1,722,612 1,496,939
assets
Property and 353,954 241,184
equipment, net
Operating lease 129,445 108,541
right-of-use assets
Goodwill 141,100 141,070
Intangible assets 353,044 373,713
Other assets 48,260 36,897
Total assets $ 2,748,415 $ 2,398,344
Liabilities and
Stockholders’
Equity
Current
liabilities:
Accounts payable $ 120,176 $ 33,156
Accrued 112,541 92,603
compensation
Contingent
consideration 45,873 21,580
payable,
current portion
Deferred revenue, 36,596 24,907
current portion
Short-term debt 80,295 80,323
financing
Other accrued 217,416 188,659
liabilities
Total current 612,897 441,228
liabilities
Contingent
consideration 83,187 96,780
payable,
long-term portion
Deferred tax
liability, 701 701
long-term
portion
Operating lease
liabilities, 142,617 118,473
long-term
portion
Deferred revenue, 15,781 17,062
long-term portion
Other liabilities 23,674 11,687
Total liabilities 878,857 685,931
Commitments and
contingencies
Stockholders’
equity:
Common stock(2) 14 14
Additional paid in 4,857,666 4,488,679
capital
Accumulated deficit -2,987,994 -2,776,022
Accumulated other -128 -258
comprehensive loss
Total stockholders’ 1,869,558 1,712,413
equity
Total liabilities
and stockholders’ $ 2,748,415 $ 2,398,344
equity
(1) The consolidated balance sheet at December 31, 2025 has been derived from
the audited consolidated financial statements at that date included in the
Company’s Annual Report on Form 10-K for the year ended December 31, 2025.
(2) As of September 30, 2026 and December 31, 2025, there were approximately
144,345,000 and 139,693,000 shares of common stock, respectively, issued and
outstanding.
Natera, Inc.
Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
(in thousands, except per share data)
Thr… Nine
mon… mon…
end… end…
Sep… Sep…
30, 30,
R… 2026 20… 2026 20…
──────────────────────────────────────────────────────────────────────────────
P… $ 78… $ 590… $ 2,… $ 1,6…
r…
L…
a… 4,… 1,9… 11… 5,9…
o…
r…
T… 79… 592… 2,… 1,6…
r…
C…
a…
e…
C…
of 27… 207… 79… 591…
p…
r…
C…
of
l… 871 548 2,… 1,4…
a…
o…
r…
R…
a… 24… 173… 68… 448…
d…
S…
g… 33… 308… 98… 885…
a…
a…
A…
of
a… 5,… — 17… —
i…
a…
T…
c… 86… 689… 2,… 1,9…
a…
e…
L…
f… -6… -97… -2… -28…
o…
I… -9… -1,… -2… -3,…
e…
I…
a…
o… 9,… 11,… 28… 35,…
i…
n…
L…
b… -5… -87… -2… -25…
i…
t…
I…
t… -2… -207 -3… -655
b…
(…
N… $ -5… $ -87… $ -2… $ -25…
l…
U…
g…
(…
on
a…
s… -20 100 130 157
a…
f…
c…
t…
a…
C… $ -5… $ -87… $ -2… $ -25…
l…
N…
l…
p…
s…
B…
a… $ -0… $ -0.… $ -1… $ -1.…
d…
W…
n…
of
s…
u…
in
c…
b…
a…
d…
n…
l…
p…
s…
B…
a… 144… 13… 142… 13…
d…